Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Daiichi Sankyo announced July 12 its factor Xa inhibitor edoxaban posted superior results to Sanofi-Aventis' Lovenox (enoxaparin), a low dose heparin, in preventing venous thromboembolic events in patients following total knee replacement. The announcement will put Daiichi Sankyo's marketing chops to the test, as the compound, while clear in its efficacy, is primed to enter a market with a number of potential factor Xa competitors in a Japanese antithrombotic market still dominated by heparin and warfarin

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts